Xeris Pharmaceuticals Inc (XERS NASDAQ) stock market data APIs
$9.3501
-0.19(-2%)
as of October 27, 2025
Try our APIs with
free plan!
Xeris Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Prev. Close
9.3501
Open
9.1646
High
9.4594
Low
9.0788
52 wk Range
2.82-9.49
Market Cap
1 503 M
Shares Outstanding
161 M
Revenue
246 M
EPS
-0.01
Beta
0.904
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Xeris Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xeris Pharmaceuticals Inc data using free add-ons & libraries
Get Xeris Pharmaceuticals Inc Fundamental Data
Xeris Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 246 M
- EBITDA: 8 381 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xeris Pharmaceuticals Inc News
New
How To YieldBoost Principal Financial Group To 12.5% Using Options
Shareholders of Principal Financial Group Inc (Symbol: PFG) looking to boost their income beyond the stock's 3.9% annualized dividend yield can sell the January 2026 covered call at the $85 strike and...
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?
Xeris Biopharma (XERS) shares ended the last trading session 14.2% higher at $9.27. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. Thi...
XERS Crosses Above Average Analyst Target
In recent trading, shares of Xeris Biopharma Holdings Inc (Symbol: XERS) have crossed above the average analyst 12-month target price of $9.00, changing hands for $9.27/share. When a stock reaches th...
After a low period, biotech stocks are on the upswing, experts say
After a period of weakness, biotech stocks are on the upswing, experts say. But bear in mind: Putting your money into biotechnology companies can lead you on something of a wild ride. The field, whic...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
